SOUTH SAN FRANCISCO, Calif.,
May 14, 2021 /PRNewswire/
-- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug
discovery, development and manufacturing company focused on the
application of precise protein engineering and rational design to
create next-generation cancer and autoimmune therapeutics, today
announced that Chief Executive Officer, Bill Newell, will present at two upcoming
virtual investor conferences on May
20 and June 2, 2021.
Presentation Details
Cowen's 2nd Annual Virtual Oncology Innovation
Summit
Event: Fireside Chat
Date: Thursday, May 20, 2021
Time: 2:40 p.m. ET / 11:40 a.m. PT
Jefferies Healthcare Conference
Event: Company
Presentation
Date: Wednesday, June 2, 2021
Time: 4:30 p.m. ET / 1:30 p.m. PT
Live webcasts of each presentation can be accessed through the
Events and Presentations page of the Investor Relations section on
the company's website at www.sutrobio.com. Archived replays of the
webcasts will be available on the company's website for
approximately 30 days following each live presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., located
in South San Francisco, is a
clinical-stage drug discovery, development and manufacturing
company. Using precise protein engineering and rational design,
Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis
platform XpressCF® and site-specific conjugation
platform XpressCF+™ led to the discovery of STRO-001 and STRO-002,
Sutro's first two internally-developed ADCs. STRO-001 is a
CD74-targeting ADC currently being investigated in a Phase 1
clinical trial of patients with advanced B-cell malignancies,
including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was
granted Orphan Drug Designation by the FDA for multiple myeloma in
October 2018. STRO-002 is a folate
receptor alpha (FolRα)-targeting ADC, currently being investigated
in a Phase 1 clinical trial of patients with ovarian and
endometrial cancers. A third product candidate, CC-99712
(BCMA-targeting ADC), which is part of Sutro's collaboration with
Bristol Myers Squibb (formerly Celgene Corporation), is enrolling
patients for its Phase 1 clinical trial of patients with multiple
myeloma and has received Orphan Drug Designation from the FDA for
multiple myeloma. A fourth product candidate, M1231, (MUC1-EGFR,
first-in-class bispecific ADC), which is part of Sutro's
collaboration with Merck KGaA, EMD Serono (EMD Serono) is enrolling
patients for its Phase 1 clinical trial of patients with metastatic
solid tumors, non-small cell lung cancer (NSCLC) and esophageal
squamous cell carcinoma. The four product candidates above being
evaluated in clinical trials resulted from Sutro's
XpressCF® and XpressCF+™ technology platforms.
Bristol Myers Squibb and EMD Serono
have worldwide development and commercialization rights for
CC-99712 and M1231, respectively, for which Sutro is entitled to
milestone or contingent payments and tiered royalties.
Sutro is dedicated to transforming the lives of cancer patients
by creating medicines with improved therapeutic profiles for areas
of unmet need. To date, Sutro's platform has led to cytokine-based
immuno-oncology therapies, ADCs, vaccines and bispecific antibodies
directed at precedented targets in clinical indications where the
current standard of care is suboptimal.
The platform allows it to accelerate discovery and development
of potential first-in-class and best-in-class molecules through
rapid and systematic evaluation of protein structure-activity
relationships to create optimized homogeneous product
candidates.
In addition to developing its own oncology pipeline, Sutro is
collaborating with select pharmaceutical and biotech companies to
discover and develop novel, next-generation therapeutics. As the
pace of clinical development accelerates, Sutro and its partners
are developing therapeutics designed to more efficiently kill
tumors without harming healthy cells.
Follow Sutro on Twitter, @Sutrobio, and
at www.sutrobio.com to learn more about our passion for
changing the future of oncology.
Investor Contacts
Annie J.
Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com
Media Contacts
Maggie
Beller
Russo Partners
(646) 942-5631
Maggie.beller@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/sutro-biopharma-to-participate-in-upcoming-virtual-investor-conferences-301291507.html
SOURCE Sutro Biopharma